Compare TARA & NSLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARA | NSLR |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.6M | 180.3M |
| IPO Year | 2014 | 2011 |
| Metric | TARA | NSLR |
|---|---|---|
| Price | $2.30 | $5.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $25.33 | $14.15 |
| AVG Volume (30 Days) | ★ 852.9K | 285.6K |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 4.63% |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ 3.89 |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.90 |
| P/E Ratio | ★ N/A | $1.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.09 | $5.35 |
| 52 Week High | $7.82 | $12.19 |
| Indicator | TARA | NSLR |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 34.75 |
| Support Level | $2.19 | N/A |
| Resistance Level | $2.73 | $6.38 |
| Average True Range (ATR) | 0.21 | 0.39 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 34.43 | 19.74 |
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Neostellar Capital Corp is an investment company focused on private, venture-backed businesses. It invests in companies that are not yet listed on a public stock exchange. It helps investors to gain exposure to a portfolio of VC-backed companies through a publicly traded stock.